Variables | Nebulized heparin (NÂ =Â 139) | Control (NÂ =Â 147) | Odds ratioa (95Â % CI) | P |
---|---|---|---|---|
Primary outcome | ||||
Ventilator-free days at day 28 | 14.0 (0.0–23.0) | 6.0 (0.0–22.0) |  | 0.459 |
(NÂ =Â 139) | (NÂ =Â 144) | Â | Â | |
Secondary outcomes | ||||
Overall mortality | 34/139 (24.5) | 35/147 (23.8) | 0.65 (0.50–1.56)b | 0.653 |
(NÂ =Â 139) | (NÂ =Â 147) | |||
PaO2/FiO2 at day seven (mmHg) | 242.5 (206.0–300.0) | 220.2 (179.4–297.7) |  | 0.098 |
(NÂ =Â 61) | (NÂ =Â 78) | |||
LIS at day seven | 2.0 (1.0–2.5) | 2.2 (1.7–3.0) |  | 0.027 |
(NÂ =Â 40) | (NÂ =Â 48) | Â | Â | |
Pneumonia during hospital stay | 48/82 (58.5) | 48/106 (45.3) | 1.49 (0.79–2.80) | 0.219 |
(NÂ =Â 82) | (NÂ =Â 106) | |||
ICU-free days at day 28 | 2.9 (0.0–19.0) | 0.0 (0.0–14.2) |  | 0.035 |
(NÂ =Â 78) | (NÂ =Â 62) | |||
Hospital-free days at day 28 | 0.0 (0.0–12.0) | 0.0 (0.0–14.0) |  | 0.951 |
(NÂ =Â 139) | (NÂ =Â 147) |